Clinical Trials Logo

Cholangiocarcinoma Recurrent clinical trials

View clinical trials related to Cholangiocarcinoma Recurrent.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03907852 Active, not recruiting - Ovarian Cancer Clinical Trials

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Start date: April 15, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.